转录组分析全面揭示儿童急性髓系白血病的遗传背景
该研究对日本AML-05试验中369例初诊儿童AML患者中的139例进行RNA测序,并结合RT-PCR在369例中鉴定出至少258种基因融合(70%)。研究新发现5种基因重排及多种罕见重排,在剩余111例中检测到KMT2A-PTD、双等位CEBPA和NPM1突变,且与基因融合互斥。结果表明RNA-seq可揭示儿童AML基因重排与突变的复杂性,提示需重新考虑风险分层。
要点
- RNA-seq在139例中检出54种框内融合和1种RUNX1框外融合。
- 369例中至少258种基因融合,占70%,含5种新发现重排。
- KMT2A-PTD、双等位CEBPA和NPM1突变与基因融合完全互斥。
核心结论
- RNA-seq揭示了儿童AML基因重排与突变的复杂性,在几乎所有患者中识别出潜在致病性改变。
- 部分儿童AML可能代表与成人不同的独立实体,提示应重新考虑风险分层。
研究设计与样本
- 对日本儿童白血病/淋巴瘤研究组AML-05试验中369例初诊儿童AML患者中的139例进行转录组分析(RNA测序)。
- 结合逆转录聚合酶链反应和RNA-seq在369例患者中鉴定基因融合。
主要发现
- RNA-seq在139例中的53例检出54种框内基因融合和1种RUNX1框外融合。
- 通过RT-PCR和RNA-seq在369例中至少发现258种基因融合,占70%。
- 新发现5种基因重排:NPM1-CCDC28A、TRIP12-NPM1、MLLT10-DNAJC1、TBL1XR1-RARB和RUNX1-FNBP1。
- 发现罕见重排:MYB-GATA1、NPM1-MLF1、ETV6-NCOA2、ETV6-MECOM、ETV6-CTNNB1、RUNX1-PRDM16、RUNX1-CBFA2T2和RUNX1-CBFA2T3。
- 在剩余111例中,KMT2A-PTD、双等位CEBPA和NPM1基因突变分别见于11、23和17例,且与任何基因融合完全互斥。
关键数值与推荐
- 儿童AML患者约40%复发,总生存率约70%。
临床怎么用
- RNA-seq可全面检测儿童AML的基因融合与突变,有助于识别潜在致病性改变。
- 基因融合与KMT2A-PTD、双等位CEBPA、NPM1突变互斥,提示风险分层需结合转录组信息重新评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recent advances in the genetic understanding of acute myeloid leukemia (AML) have improved clinical outcomes in pediatric patients. However, ∼40% of patients with pediatric AML relapse, resulting in a relatively low overall survival rate of ∼70%. The objective of this study was to reveal the comprehensive genetic background of pediatric AML. We performed transcriptome analysis (RNA sequencing [RNA-seq]) in 139 of the 369 patients with de novo pediatric AML who were enrolled in the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 trial and investigated correlations between genetic aberrations and clinical information. Using RNA-seq, we identified 54 in-frame gene fusions and 1 RUNX1 out-of-frame fusion in 53 of 139 patients. Moreover, we found at least 258 gene fusions in 369 patients (70%) through reverse transcription polymerase chain reaction and RNA-seq. Five gene rearrangements were newly identified, namely, NPM1-CCDC28A, TRIP12-NPM1, MLLT10-DNAJC1, TBL1XR1-RARB, and RUNX1-FNBP1. In addition, we found rare gene rearrangements, namely, MYB-GATA1, NPM1-MLF1, ETV6-NCOA2, ETV6-MECOM, ETV6-CTNNB1, RUNX1-PRDM16, RUNX1-CBFA2T2, and RUNX1-CBFA2T3. Among the remaining 111 patients, KMT2A-PTD, biallelic CEBPA, and NPM1 gene mutations were found in 11, 23, and 17 patients, respectively. These mutations were completely mutually exclusive with any gene fusions. RNA-seq unmasked the complexity of gene rearrangements and mutations in pediatric AML. We identified potentially disease-causing alterations in nearly all patients with AML, including novel gene fusions. Our results indicated that a subset of patients with pediatric AML represent a distinct entity that may be discriminated from their adult counterparts. Based on these results, risk stratification should be reconsidered.
引用
- Shiba N, Yoshida K, Hara Y, et al. Transcriptome analysis offers a comprehensive illustration of the genetic background of pediatric acute myeloid leukemia. Blood Adv. 2019. PMID: 31648321. doi:10.1182/bloodadvances.2019000404
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。